Last reviewed · How we verify
Daratumumab, dexamethasone, ixazomib, pomalidomide
At a glance
| Generic name | Daratumumab, dexamethasone, ixazomib, pomalidomide |
|---|---|
| Also known as | daratumumab: Darzalex, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst |
| Sponsor | Multiple Myeloma Research Consortium |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (PHASE3)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma (PHASE2)
- Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (PHASE2)
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (PHASE1, PHASE2)
- Myeloma-Developing Regimens Using Genomics (MyDRUG) (PHASE1, PHASE2)
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: